<DOC>
	<DOCNO>NCT00214604</DOCNO>
	<brief_summary>Evaluation efficacy rosuvastatin 10mg , rosuvastatin 20mg pravastatin 40mg subject dysbetalipoproteinemia .</brief_summary>
	<brief_title>Type III Dysbetalipoproteinemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type III</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Lipid Regulating Agents</mesh_term>
	<criteria>Diagnosis dysbetalipoproteinemia define VLDLC/VLDLTG mass ratio &gt; 0.35 Visit 2 concurrence mixed hyperlipidemia ( fast TC ≥ 200mg/dL , fast TG ≥ 200mg/dL Visits 2 3 ) genotype ApoE publish associate dysbetalipoproteinemia Use cholesterollowering drug , lipid lower dietary supplement food additive Visit 1 except accordance protocol coadministered therapy ( i.e. , fenofibrate ) rosuvastatin 40mg Weeks 30 36 ; current active liver disease hepatic dysfunction , serum CK ≥ 3 time ULN ( unless explain exercise ) anytime dietary period , serum creatinine &gt; 2.0 mg/dL history renal transplantation treatment phase , fast triglyceride &gt; 1000 mg/dL time dietary leadin history pancreatitis treatment dysbetalipoproteinemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>